Why the study?
Does MNC secretome reduce myocardial inflammation in a mouse model of experimental autoimmune myocarditis?
Does MNC secretome reduce myocardial inflammation in a mouse model of experimental autoimmune myocarditis?
MNC secretome attenuates myocardial inflammation in a mouse model of autoimmune myocarditis, suggesting a potential novel treatment for inflammatory heart diseases.
Answers are grounded in this paper and cite their sources.
May inform immunomodulatory strategies in myocarditis; leaves open translation from murine model to patients.
AIMS: Supernatants of serum-free cultured mononuclear cells (MNC) contain a mix of immunomodulating factors (secretome), which have been shown to attenuate detrimental inflammatory responses following myocardial ischaemia. Inflammatory dilated cardiomyopathy (iDCM) is a common cause of heart failure in young patients. Experimental autoimmune myocarditis (EAM) is a CD4+ T cell-dependent model, which mirrors important pathogenic aspects of iDCM. The aim of this study was to determine the influence of MNC secretome on myocardial inflammation in the EAM model. METHODS AND RESULTS: BALB/c mice were immunized twice with an alpha myosin heavy chain peptide together with Complete Freund adjuvant. Supernatants from mouse mononuclear cells were collected, dialysed, and injected i.p. at Day 0, Day 7, or Day 14, respectively. Myocarditis severity, T cell responses, and autoantibody formation were assessed at Day 21. The impact of MNC secretome on CD4+ T cell function and viability was evaluated using in vitro proliferation and cell viability assays. A single high-dose application of MNC secretome, injected at Day 14 after the first immunization, effectively attenuated myocardial inflammation. Mechanistically, MNC secretome induced caspase-8-dependent apoptosis in autoreactive CD4+ T cells. CONCLUSION: MNC secretome abrogated myocardial inflammation in a CD4+ T cell-dependent animal model of autoimmune myocarditis. This anti-inflammatory effect of MNC secretome suggests a novel and simple potential treatment concept for inflammatory heart diseases.
No takes yet. Share an insight, caveat, or question.
Höetzenecker et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: